GDF-11

What is GDF-11?

Growth differentiation factor 11 (GDF-11, also known as BMP-11) is an endogenous secreted peptide of the TGF-β superfamily, closely related to myostatin (GDF-8) — the two share approximately 90% amino acid identity in the mature signaling domain. GDF-11 is encoded by the GDF11 gene and is expressed broadly across tissues including cardiac muscle, skeletal muscle, brain, kidney, liver, and others. The mature peptide signals through TGF-β superfamily receptors (ActRIIA, ActRIIB, ALK4, ALK5) with extensive overlap with myostatin signaling. The biological role of GDF-11 in adult tissues was relatively obscure until the 2013 Loffredo Cell paper from Amy Wagers' group at Harvard, which used heterochronic parabiosis (surgical joining of young and aged mouse circulations) to identify GDF-11 as a circulating factor declining with age and capable of reversing age-related cardiac hypertrophy when administered to aged mice. The paper generated substantial public attention as a candidate 'rejuvenation peptide' and prompted extensive follow-up research. The rejuvenation story has been substantially complicated since 2013. Egerman and colleagues at Novartis (2015 Cell Metabolism, plus the 2019 Egerman/Glass review in Critical Reviews in Biochemistry and Molecular Biology, PMID 31144559) reported that the original antibody used in the Loffredo work had cross-reactivity issues with myostatin, that GDF-11 levels actually increase rather than decrease with age in some populations, and that direct GDF-11 administration produces muscle-impairing effects through the same activin-receptor pathway as myostatin. Subsequent work has been mixed — some studies have replicated cardiac and other rejuvenation effects under specific conditions; others have reported negative or even harmful effects. The 2023 Kraler Cardiovasc Res paper (PMID 37742057) reported that circulating GDF-11 exacerbates myocardial injury in mice and associates with increased infarct size in humans, directly contradicting the rejuvenation framing for cardiac context. As of 2026, the GDF-11 story is one of the most contested in modern aging biology — real biology, contradictory literature, no clinical translation, no FDA-approved product. GDF-11 is sold through research-channel and grey-market sources but should be considered an unsettled research peptide rather than a validated rejuvenation therapy.

What GDF-11 Is Investigated For

GDF-11 is a contested-biology research-peptide topic, not a validated clinical rejuvenation therapy. The original 2013 Loffredo/Wagers Cell paper from the Harvard Stem Cell Institute used heterochronic parabiosis to identify GDF-11 as a candidate young-blood rejuvenation factor that declines with age and reverses age-related cardiac hypertrophy when administered to aged mice. The paper generated substantial public attention and a wave of follow-up research extending the GDF-11 framing to skeletal muscle regeneration, hippocampal neurogenesis, vascular and bone effects, and other aging-relevant outcomes. The Egerman/Glass 2015 Cell Metabolism counter-paper from Novartis identified antibody specificity issues with the original work, reported that GDF-11 actually increases rather than decreases with age in some populations, and showed that direct GDF-11 administration produces myostatin-like muscle-impairing effects through shared activin-receptor signaling. The 2019 Egerman/Glass Critical Reviews in Biochemistry and Molecular Biology consolidation review (PMID 31144559) provides the comprehensive case for the contradicting evidence. The 2023 Kraler Cardiovasc Res paper (PMID 37742057) extended the contradiction to cardiac context, reporting that circulating GDF-11 exacerbates myocardial injury in mice and associates with increased infarct size in humans. The honest framing as of 2026 is that GDF-11 is real biology — a TGF-β superfamily peptide with established receptor pharmacology, embryonic developmental functions, and adult tissue expression — but its proposed role as an aging-rejuvenation factor is unsettled. The original rejuvenation findings have not been consistently replicated, the directionality of GDF-11 changes with age is contested, and direct GDF-11 administration may produce harmful rather than beneficial effects in some contexts. No FDA-approved GDF-11 product exists for any indication, and GDF-11 sold through research-channel and grey-market sources should not be considered a validated rejuvenation therapy. The class is a useful teaching example for the difficulty of validating circulating-factor aging claims and for the importance of antibody specificity in biomarker-driven aging research.

History & Discovery

GDF-11 was characterized as a TGF-β superfamily member in the late 1990s and early 2000s through molecular cloning and developmental biology work. The peptide's role in embryonic development — including axial skeletal patterning and limb development through Smad2/3 signaling — was established before its adult-tissue and circulating-factor roles became prominent. The modern era of GDF-11 research was launched by the 2013 Loffredo Cell paper from Amy Wagers' and Richard Lee's groups at the Harvard Stem Cell Institute and the Brigham and Women's Hospital. The paper used heterochronic parabiosis (the surgical joining of young and aged mouse circulations) — a classical aging biology technique that had been used for decades to identify circulating factors mediating the rejuvenation effects observed when aged mice receive young blood circulation. Mass spectrometry-based proteomic analysis of plasma identified GDF-11 as a candidate factor declining with age in the parabiosis system, and recombinant GDF-11 administration to aged mice was reported to reverse age-related cardiac hypertrophy. The paper generated substantial public and scientific attention, prompting a wave of follow-up research extending the GDF-11 framing to skeletal muscle regeneration (Sinha et al. 2014 Science), hippocampal neurogenesis (Katsimpardi et al. 2014 Science), and other aging-relevant outcomes. The Egerman/Glass 2015 Cell Metabolism paper from David Glass's group at the Novartis Institutes for Biomedical Research initiated the substantial counter-evidence trajectory. The paper identified key issues with the original Loffredo work: antibody cross-reactivity between GDF-11 and myostatin in the assays used to measure plasma GDF-11; improved measurements showing that GDF-11 actually increases rather than decreases with age in mouse and human populations; and direct recombinant GDF-11 administration to mice producing skeletal muscle wasting and impaired regeneration — the same direction as myostatin agonism rather than the opposite. The Egerman/Glass 2019 Critical Reviews in Biochemistry and Molecular Biology review (PMID 31144559) consolidated the contradicting evidence and laid out the methodological case for caution in interpreting circulating-factor aging claims based on antibody-dependent measurements. The 2023 Kraler Cardiovascular Research paper from a Swiss-led team (PMID 37742057) extended the contradicting evidence to cardiac injury context. Circulating GDF-11 was reported to exacerbate myocardial injury in murine models of myocardial infarction and to associate with increased infarct size in human MI patients — a direction directly opposite the cardiac rejuvenation framing of the original 2013 Loffredo paper. The broader aging biology field has not converged on a settled directional understanding of GDF-11 as of 2026. Some research groups continue to publish results consistent with the original Loffredo rejuvenation framing under specific tissue, dose, and developmental contexts; others have reported neutral or contradicting findings. No FDA-approved GDF-11 product exists for any indication, no clinical translation has advanced, and the methodological challenges of antibody specificity and assay validation continue to complicate interpretation of plasma GDF-11 measurements. The class is a useful teaching example for the difficulty of validating circulating-factor aging claims and for the importance of rigorous antibody validation in biomarker-driven research.

How It Works

GDF-11 is a small protein your body produces that's nearly identical to myostatin — the famous protein that limits muscle growth. In 2013, Harvard researchers reported that aged mice given GDF-11 had reversed age-related heart enlargement, suggesting GDF-11 was a 'youth factor.' That made GDF-11 famous overnight. But other research groups (including a major paper from Novartis in 2015 and another from a Swiss-led team in 2023) have reported the opposite — that GDF-11 actually goes up with age, that giving GDF-11 hurts skeletal muscle the same way myostatin does, and that high GDF-11 makes heart attacks worse. The aging-rejuvenation story for GDF-11 hasn't held up, and the peptide is not a validated anti-aging treatment despite its consumer-research-channel availability.

GDF-11 is a 109-residue mature peptide cleaved from a longer precursor (407-residue prepropeptide encoded by the GDF11 gene on human chromosome 12q13.2). The mature peptide signals through TGF-β superfamily receptors as a homodimer or as part of latent complexes with the GDF-11 propeptide and follistatin-related proteins — extensively overlapping with myostatin signaling because of the ~90% amino acid identity in the mature domain. The receptor binding profile includes ActRIIA, ActRIIB (the principal myostatin/GDF-11 receptor), ALK4, and ALK5, with downstream Smad2/3 phosphorylation and transcriptional regulation of TGF-β-responsive genes including Smad7, p21, and various tissue-specific targets. The 2013 Loffredo/Wagers Cell paper used heterochronic parabiosis (surgical joining of young and aged mouse circulations) to identify circulating factors mediating the cardiac-rejuvenation effects observed when aged mice receive young blood circulation. Mass spectrometry-based proteomic analysis of plasma identified GDF-11 as a candidate factor declining with age. Recombinant GDF-11 administration to aged mice was reported to reverse age-related cardiac hypertrophy. The paper generated substantial follow-up research framed around 'GDF-11 as rejuvenation factor,' including extensions to skeletal muscle regeneration, hippocampal neurogenesis, and vascular biology. The Egerman/Glass 2015 Cell Metabolism counter-paper from Novartis identified key issues with the original work. The original antibody used to measure GDF-11 in plasma cross-reacted with myostatin, complicating the directional interpretation. Improved measurement methods showed that GDF-11 actually increases rather than decreases with age in mouse and human populations. Direct recombinant GDF-11 administration to mice produced skeletal muscle wasting and impaired regeneration — the same direction as myostatin agonism, consistent with the shared receptor pharmacology rather than opposing it. The 2019 Egerman/Glass Critical Reviews in Biochemistry and Molecular Biology review (PMID 31144559) consolidated the contradicting evidence and laid out the methodological case for caution in interpreting circulating-factor aging claims based on antibody-dependent measurements. The 2023 Kraler Cardiovasc Res paper (PMID 37742057) extended the contradicting evidence to cardiac context. Circulating GDF-11 was reported to exacerbate myocardial injury in murine models of myocardial infarction and to associate with increased infarct size in human patients. The cardiac-injury-exacerbating direction directly contradicts the rejuvenation framing of the original 2013 Loffredo paper for cardiac biology. The broader aging biology field has not converged on a settled directional understanding of GDF-11. Some research groups continue to publish results consistent with the original Loffredo framing under specific tissue, dose, and developmental contexts; others have reported neutral or contradicting findings. The methodological challenges include antibody specificity (myostatin vs GDF-11 cross-reactivity), assay sensitivity, the difficulty of interpreting bulk-plasma concentrations of a TGF-β superfamily ligand that is also processed and stored in latent complexes with propeptides and follistatin-related proteins, and the tissue-context-dependent pharmacology that may produce different outcomes in different organ systems. As of 2026, GDF-11 is best understood as real biology with contested aging-relevance interpretation rather than as a validated rejuvenation factor or a validated harmful aging mediator.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about GDF-11:

• 01Whether GDF-11 actually declines with age in humans, or whether the original Loffredo findings reflected antibody specificity artifacts that have been corrected in subsequent work showing age-related increase or unchanged levels.
• 02Whether direct exogenous GDF-11 administration produces tissue-specific differential effects (e.g. cardiac rejuvenation vs skeletal muscle wasting) that could explain the contradictory findings, or whether the tissue-context-specific effects argument is itself an artifact.
• 03Whether circulating GDF-11 measurement has any clinically meaningful biomarker value once antibody specificity is properly addressed across studies.
• 04Whether selective GDF-11 receptor pharmacology (distinguishing GDF-11 from myostatin signaling at ActRIIB) is achievable as a research tool or therapeutic strategy, or whether the receptor-overlap is too tight for selectivity.
• 05Whether the broader 'young blood as rejuvenation' framing remains scientifically supported beyond GDF-11 specifically — the heterochronic parabiosis literature has identified other candidate factors (TIMP-2, beta-2 microglobulin in some contexts, etc.) with their own replication histories.
• 06Whether GDF-11 has clinically meaningful roles in any specific disease context (cardiac injury, muscle wasting, neurological aging, etc.) once the antibody specificity issues are addressed and the contradicting evidence is reconciled.

Forms & Administration

GDF-11 is not formulated or approved as a therapeutic in any jurisdiction. Research applications use recombinant GDF-11 (typically the mature dimer form) for in vitro receptor binding and signaling assays, ex vivo tissue pharmacology, and intraperitoneal or subcutaneous administration in animal aging and tissue regeneration studies. The administration in research literature has typically used daily intraperitoneal injection over days to weeks. Compounded or research-chemical-channel GDF-11 has no validated clinical use, no human safety database, and no consensus on appropriate dosing if any.

Common Questions

Who GDF-11 Is NOT For

Drug & Supplement Interactions

There is no validated human drug-interaction profile for GDF-11. Theoretical interactions follow from the shared activin-receptor signaling with myostatin: GDF-11 administration would be expected to oppose the effects of myostatin-pathway antagonists (the various ActRIIB-targeting biologics in development for muscle wasting and DMD — apitegromab, bimagrumab historically, and others), to interact with TGF-β-pathway-modifying agents in unpredictable ways, and to potentially interact with cardiac medications given the contradicting cardiac-injury-exacerbation evidence. None of these interactions has been characterized in controlled human studies; they are mechanistic possibilities argued from receptor pharmacology that argue against casual exogenous GDF-11 exposure outside controlled research settings.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions